# HNRNPA0

## Overview
HNRNPA0 is a gene that encodes the protein heterogeneous nuclear ribonucleoprotein A0 (hnRNP A0), which is a member of the hnRNP A/B family of RNA-binding proteins. These proteins are integral to various aspects of RNA metabolism, including mRNA stability, splicing, and transport. HnRNP A0 is characterized by its two N-terminal RNA recognition motifs and a C-terminal glycine-rich low-complexity domain, which facilitate its interactions with RNA and other proteins (Thibault2021hnRNP). The protein is primarily localized in the nucleus but can shuttle to the cytoplasm, where it plays a role in regulating gene expression and cellular stress responses (Thibault2021hnRNP). HnRNP A0 is particularly significant in the regulation of inflammatory mediators and has been implicated in cancer progression through its interactions with mRNAs of inflammatory cytokines and tumor-associated genes (Konishi2020A; Rousseau2002Inhibition). The gene's clinical significance is underscored by its association with various cancers, where mutations and expression alterations contribute to disease pathogenesis (Wei2015Mutations; Thibault2021hnRNP).

## Structure
HNRNPA0 is a member of the hnRNP A/B family, characterized by two N-terminal RNA recognition motifs (RRMs) and a C-terminal glycine-rich low-complexity domain (LCD) (Thibault2021hnRNP). The LCD includes an RGG motif region, which is involved in RNA binding and protein-protein interactions (Rousseau2002Inhibition). HNRNPA0 is unique in that it lacks an intron/exon structure, encoding a single isoform, A0, derived from reverse transcription of mRNA (Thibault2021hnRNP). 

The protein undergoes post-translational modifications, notably phosphorylation at the Ser84 site by MAPKAP-K2, which is significant for its role in inflammatory responses and cancer progression (Konishi2020A; Rousseau2002Inhibition). This phosphorylation affects its interaction with mRNAs of inflammatory mediators and tumor-associated mRNAs, influencing mRNA stability and expression (Konishi2020A; Rousseau2002Inhibition). 

HNRNPA0 shares 53-56% amino acid identity with major A2/B1 isoforms and 58% with A3, and it is less abundant than other hnRNP proteins (Thibault2021hnRNP). Despite its structural similarities with other hnRNP A/B proteins, specific details on its primary, secondary, tertiary, or quaternary structures are not provided in the available literature.

## Function
HNRNPA0 is a member of the heterogeneous nuclear ribonucleoproteins (hnRNPs) family, which are RNA-binding proteins involved in various aspects of RNA metabolism. In healthy human cells, HNRNPA0 plays a crucial role in RNA processing, including mRNA stability, splicing, and transport. It is primarily localized in the nucleus but also shuttles to the cytoplasm, where it influences gene expression and cellular stress responses (Thibault2021hnRNP).

HNRNPA0 is involved in the regulation of inflammatory mediators by binding to AU-rich elements (AREs) in the 3'-untranslated regions of mRNAs. This binding is crucial for the post-transcriptional regulation of mRNA stability and translation, particularly in response to inflammatory stimuli (Rousseau2002Inhibition). The protein is phosphorylated by MAPKAP-K2 at Ser84, a modification that enhances its interaction with cytokine mRNAs, such as those encoding TNF-a, COX-2, and MIP-2, thereby affecting their stabilization and translation (Rousseau2002Inhibition).

HNRNPA0 also plays a role in cell cycle regulation and apoptosis. It is involved in stabilizing mRNAs that are crucial for cell cycle arrest and apoptosis, acting as a backup mechanism when p53 fails, thus preventing apoptosis and conferring resistance to chemotherapy (Thibault2021hnRNP).

## Clinical Significance
Mutations and alterations in the expression of the HNRNPA0 gene have been linked to various cancers. In colorectal cancer, mutations in the upstream transcriptional regulatory region of HNRNPA0 are associated with an increased risk, and hypermethylation of the gene correlates with poor prognosis in clear cell renal carcinoma (Thibault2021hnRNP). The gene's role in cancer is further highlighted by its involvement in cell cycle regulation and apoptosis, where its knockdown increases cancer cell susceptibility to chemotherapy (Thibault2021hnRNP).

In familial cancer studies, mutations in HNRNPA0 have been associated with elevated cancer risk, particularly in a large family with multiple early-onset cancers. These mutations affect expression patterns in key signaling pathways involved in cancer development (Wei2015Mutations). The gene's haploinsufficiency is also implicated in therapy-related myeloid neoplasms and acute myeloid leukemia with chromosome 5q deletions, where reduced expression shifts myeloid differentiation and contributes to leukemogenesis (Young2014Knockdown).

In colorectal cancer, hnRNP A0 is phosphorylated, stabilizing tumor-associated mRNAs and promoting excessive mitosis. Its downregulation leads to cell cycle arrest and apoptosis, suggesting its potential as a therapeutic target (Konishi2020A).

## Interactions
HNRNPA0 interacts with various proteins and nucleic acids, playing a significant role in mRNA regulation. It is a major substrate for MAPKAP-K2, a kinase activated by SAPK2a/p38, and its phosphorylation at Ser84 is crucial for its function. This phosphorylation is induced by lipopolysaccharide (LPS) stimulation and is inhibited by the SAPK2a/p38 inhibitor SB 203580 (Rousseau2002Inhibition). HNRNPA0 binds to AU-rich elements (AREs) in the 3'-untranslated regions of mRNAs encoding inflammatory cytokines such as TNF-a, COX-2, and MIP-2, contributing to the stabilization and translation of these mRNAs (Rousseau2002Inhibition).

HNRNPA0 also interacts with other proteins involved in mRNA regulation, including TIA-1, hnRNP A1, and hnRNP D (Rousseau2002Inhibition). In the context of cancer, phosphorylated HNRNPA0 stabilizes mRNAs such as NUDT12, OPN3, and RAB3GAP1, which are crucial for tumor mitotic events (Konishi2020A). The interaction between HNRNPA0 and these mRNAs is modulated by its phosphorylation state, which is a key step in cancer progression (Konishi2020A). Additionally, HNRNPA0 has been shown to interact with the HIV-1 genome, particularly within the LTR region, suggesting a role in limiting HIV-1 production (Roesmann2023Cellular).


## References


[1. (Wei2015Mutations) Chongjuan Wei, Bo Peng, Younghun Han, Wei V. Chen, Joshua Rother, Gail E. Tomlinson, C. Richard Boland, Marc Chaussabel, Marsha L. Frazier, and Christopher I. Amos. Mutations of hnrnpa0 and wif1 predispose members of a large family to multiple cancers. Familial Cancer, 14(2):297–306, February 2015. URL: http://dx.doi.org/10.1007/s10689-014-9758-8, doi:10.1007/s10689-014-9758-8. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10689-014-9758-8)

[2. (Thibault2021hnRNP) Patricia A. Thibault, Aravindhan Ganesan, Subha Kalyaanamoorthy, Joseph-Patrick W. E. Clarke, Hannah E. Salapa, and Michael C. Levin. Hnrnp a/b proteins: an encyclopedic assessment of their roles in homeostasis and disease. Biology, 10(8):712, July 2021. URL: http://dx.doi.org/10.3390/biology10080712, doi:10.3390/biology10080712. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biology10080712)

[3. (Young2014Knockdown) D. J. Young, A. Stoddart, J. Nakitandwe, S.-C. Chen, Z. Qian, J. R. Downing, and M. M. Le Beau. Knockdown of hnrnpa0, a del(5q) gene, alters myeloid cell fate in murine cells through regulation of au-rich transcripts. Haematologica, 99(6):1032–1040, February 2014. URL: http://dx.doi.org/10.3324/haematol.2013.098657, doi:10.3324/haematol.2013.098657. This article has 23 citations.](https://doi.org/10.3324/haematol.2013.098657)

[4. (Rousseau2002Inhibition) S. Rousseau. Inhibition of sapk2a/p38 prevents hnrnp a0 phosphorylation by mapkap-k2 and its interaction with cytokine mrnas. The EMBO Journal, 21(23):6505–6514, December 2002. URL: http://dx.doi.org/10.1093/emboj/cdf639, doi:10.1093/emboj/cdf639. This article has 169 citations.](https://doi.org/10.1093/emboj/cdf639)

5. (Roesmann2023Cellular) Cellular hnRNPA0 limits HIV-1 production by interference with LTR-activity and programmed ribosomal frameshifting. This article has 1 citations.

[6. (Konishi2020A) Hiroaki Konishi, Mikihiro Fujiya, Shin Kashima, Aki Sakatani, Tatsuya Dokoshi, Katsuyoshi Ando, Nobuhiro Ueno, Takuya Iwama, Kentaro Moriichi, Hiroki Tanaka, and Toshikatsu Okumura. A tumor-specific modulation of heterogeneous ribonucleoprotein a0 promotes excessive mitosis and growth in colorectal cancer cells. Cell Death &amp; Disease, April 2020. URL: http://dx.doi.org/10.1038/s41419-020-2439-7, doi:10.1038/s41419-020-2439-7. This article has 17 citations.](https://doi.org/10.1038/s41419-020-2439-7)